Medical devices, healthcare technology and the business of care
PMA approval · P250005

Idylla CDx MSI Test

Biocartis Us, Inc. · Decision date Aug 15, 2025

FDA DECISIONP250005

What did the FDA approve?

FDA records P250005 as an original PMA application. The recorded decision is approval, dated Aug 15, 2025.

FDA approval order statement

For in vitro diagnostic use. For Prescription Use Only. For use on the Biocartis Idylla System only.The Idylla CDx MSI Test is an in vitro diagnostic test intended for the qualitative detection of a panel of seven monomorphic biomarkers (ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A and SULF2) for identification of microsatellite instability (MSI) in colorectal cancer (CRC) tissue. The Idylla CDx MSI Test uses formalin-fixed, paraffin embedded (FFPE) tissue sections from patients with CRC, from which nucleic acids are extracted, then analyzed using PCR amplification and subsequent melt-curve analysis. The Idylla CDx MSI Test reports MSI status as either Microsatellite Stable (MSS) or Microsatellite Instability-High (MSI-H) or invalid. The test is intended as a companion diagnostic to identify CRC patients with MSI-H status, who may benefit from treatment with OPDIVO (nivolumab) as a monotherapy and/or treatment with OPDIVO (nivolumab) in combination with YERVOY (ipilimumab).
Regulatory pathway
Original PMA
Clinical specialty
Medical Genetics
Decision date
Aug 15, 2025

FDA source record

Regulatory record facts

Identifier
P250005
Regulatory pathway
Premarket approval application
Product code
SFL
Decision code
APPR
Decision date
Aug 15, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Nucleic Acid Based Assay, Microsatellite Instability.

Product code
SFL
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250005 received

    Application receipt date recorded by FDA.

  2. P250005 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P250005. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code SFL

Product / regulatory recordCompanyPathwayDecision dateSource
Promega CorporationPMA approvalSep 15, 2026FDA
Promega CorporationPMA approvalNov 5, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biocartis Us, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Two Pierce Pl., Suite 1510, Itasca, IL, 60174

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records